SPDL1 and lymphoma: In general, the reduction of sPD-L1 levels during treatment was predictive of better prognosis for a variety of cancers, [126] including GC, [91] metastatic ccRCC, [120] biliary tract cancer, [101] TNBC, [65] lymphoma,[26, 107, 127] pancreatic cancer, [115] CRC, [109] and NSCLC, [67] regardless to treatment modalities.